Researchers compared herbal oils with minoxidil, modest help emerged

Daily scalp care gains a clearer map, with rosemary held as a mild choice and minoxidil kept as the reference. Clarity grew around the June 2026 guide and a 90 day trial reported before 10 September 2026.

In 2015 Panahi and colleagues gave 100 people with androgenetic alopecia rosemary oil or minoxidil 2 percent for six months. Each group recorded significant growth in hair count from the starting point and the groups did not differ significantly from each other. Scalp itch was more common with minoxidil, at 44.4 percent against 15 percent for rosemary, and dandruff was more common with minoxidil, at 32.2 percent against 7.5 percent for rosemary.

In 2020 Nasirian and colleagues gave 60 participants 2 percent rosemary oil or 2 percent minoxidil for 24 weeks. Counts increased 10% with rosemary and 13% with minoxidil, with p equals 0.12. The near result deserves attention, and the strength deserves attention too. Those studies tested 2% minoxidil, not the stronger 5% preparation used by many adults, so similarity there does not show sameness with present standard dosing.

The latest rosemary evidence combines the herb with lavender against a control. Patel and colleagues assigned 90 participants in 2025 to rosemary-lavender oil, a peptide preparation or control for 90 days. The rosemary lavender group lifted hair growth rate by 57.73 percent over control at p less than 0.0001. That group also raised thickness by 68.70% and density by about 32% against control, while shedding dropped by more than 40%.

Bench research suggests a possible mechanism. Murata and colleagues found in 2013 that rosemary leaf extract blocked 5-alpha reductase by 82.4% at 200 ug per mL and 94.6% at 500 ug per mL in vitro. In that same test finasteride gave 81.9% inhibition. Results in glass do not foretell results on skin.

Peptides still sit earlier in the evidence root system. A phase 2A trial of PP405, a peptide that wakes hair follicle stem cells, showed statistically meaningful regrowth in eight weeks across 78 patients. A telogen effluvium study enrolled 45 subjects aged 18 to 45 years in three groups of 15 for 90 days, testing Capilia longa blends, cytokine and peptide blends, and redensyl with aminexil at 2 mL once daily. Samples remain small, follow up stays short and formulas differ.

Low dose oral minoxidil is moving from clinic habit toward shared rules. An international consensus on starting and monitoring took 4th place as a poster at the 2024 American Academy of Dermatology Annual Meeting. It gave daily ranges of 0.625 to 2.5 mg for adolescent females, 0.625 to 5 mg for adult females, and 1.25 to 5 mg for adolescent and adult males. Visible benefit is usually seen between 3 to 6 months of steady use. That direction rests on expert consensus because larger trials are limited. A meta analysis found platelet rich plasma clearly lifted hair count and density over controls. “Regenerative therapies like PRP have become an important part of how we approach early hair loss, because they use the bodys own healing signals,” said Dr. Lindsay Bordone, MD, FAAD, dermatologist at Columbia University and the American Academy of Dermatology.

For a slow routine, the exchange is clear. Rosemary calls for steady daily use and patience, with less itch in these trials but without proof of lasting gains after stopping. It remains unknown whether store oils equal standardized preparations or equal minoxidil 5 percent over 12 months.

Look for broader studies that use standard 5% dosing, named peptide doses and longer follow up.